Review of Charts From Amish/Mennonite Variant PA Patients
Chart Review of Patients Who Have the Amish/Mennonite Variant of Propionic Acidemia
1 other identifier
observational
38
1 country
1
Brief Summary
The natural history of patients with PA-AMV has not been systematically studied before and there is no published data in the literature about this condition since 1980. There is no evidence-based approach to care of these patients, particularly the younger patients who may no come to medical attention until significant cardiac problems develop. Through systematic review of existing medical records on essentially all known patient with this condition, investigators plan to develop an evidence-based management plan for preventive care of these patients.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for all trials
Started Apr 2017
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
April 6, 2017
CompletedFirst Submitted
Initial submission to the registry
April 12, 2017
CompletedFirst Posted
Study publicly available on registry
May 18, 2017
CompletedPrimary Completion
Last participant's last visit for primary outcome
September 5, 2022
CompletedStudy Completion
Last participant's last visit for all outcomes
September 5, 2022
CompletedJanuary 29, 2026
January 1, 2026
5.4 years
April 12, 2017
January 27, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Clinical and biochemical natural history of Amish/Mennonite PA variant
Chart review to describe clinical and biochemical features of Amish/Mennonite PA variant
Through study completion, an average of one year.
Eligibility Criteria
Amish and Mennonite individuals who have been diagnosed as having the PA-AMV form of propionic academia as characterized by the presence of homozygous PCCB c.1060A\>G.
You may qualify if:
- Patients homozygous for the PCCB c.606A\>G mutation
You may not qualify if:
- Patients who are not homozygous for the PCCB c.1606A\>G mutation
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Children's Hospital of Pittsburgh
Pittsburgh, Pennsylvania, 15224, United States
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Lina Ghaloul-Gonzalez, MD
University of Pittsburgh
Study Design
- Study Type
- observational
- Observational Model
- CASE ONLY
- Time Perspective
- CROSS SECTIONAL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Assistant Professor
Study Record Dates
First Submitted
April 12, 2017
First Posted
May 18, 2017
Study Start
April 6, 2017
Primary Completion
September 5, 2022
Study Completion
September 5, 2022
Last Updated
January 29, 2026
Record last verified: 2026-01
Data Sharing
- IPD Sharing
- Will not share